P
Pamela B. Landsman
Researcher at Merck & Co.
Publications - 16
Citations - 4400
Pamela B. Landsman is an academic researcher from Merck & Co.. The author has contributed to research in topics: Diabetes mellitus & Metabolic syndrome. The author has an hindex of 10, co-authored 16 publications receiving 4203 citations.
Papers
More filters
Journal ArticleDOI
Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis
TL;DR: It is concluded that history of prior fracture at any site is an important risk factor for future fractures and patients with a history of Prior fracture should receive further evaluation for osteoporosis and fracture risk.
Journal ArticleDOI
NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older
TL;DR: Among people with diabetes, the prevalence of metabolic syndrome was very high, and those with diabetes and metabolic syndrome had the highest prevalence of CHD, compared with those with both metabolic syndrome and diabetes, who had the lowest prevalence.
Journal ArticleDOI
Pharmacy Benefits and the Use of Drugs by the Chronically Ill
Dana P. Goldman,Geoffrey F. Joyce,José J. Escarce,Jennifer E. Pace,Matthew D. Solomon,Marianne Laouri,Pamela B. Landsman,Steven M. Teutsch +7 more
TL;DR: The use of medications such as antihistamines and NSAIDs, which are taken intermittently to treat symptoms, was sensitive to co-payment changes, and other medications--antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiulcerant, and antidiabetic agents--also demonstrated significant price responsiveness.
Journal ArticleDOI
Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease.
TL;DR: In this article, the authors found that patients with impaired fasting glucose levels have an increased risk of coronary heart disease (CHD), compared with those with normal FG, and the frequency of known CHD risk factors also increased with worsening glucose status.
Journal Article
Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization.
TL;DR: Use of retail prescription medications within 9 specific therapeutic classes decreased as copayments increased, and demand for pharmaceuticals was relatively inelastic with these copayment increases.